Billionaire Shanghvi’s Sun Gains After Cancer Drug Approval

Sun Pharmaceutical Industries Ltd., controlled by Indian billionaire Dilip Shanghvi, rose the most in 14 months after the U.S. approved the company’s generic version of Johnson & Johnson’s cancer drug Doxil.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.